{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:08:31Z","timestamp":1789927711725,"version":"4.0.1"},"reference-count":54,"publisher":"Informa UK Limited","issue":"1","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2017,1,2]]},"DOI":"10.1080\/17474086.2017.1262757","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T14:37:57Z","timestamp":1479739077000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":47,"title":["Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma"],"prefix":"10.1080","volume":"10","author":[{"given":"Tapan M.","family":"Kadia","sequence":"first","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[{"name":",","place":["USA"]},{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,12,8]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"issue":"23","key":"e_1_3_2_4_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V126.23.1.1","article-title":"Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-Negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized graall-R 2005 study","volume":"126","author":"Maury S","year":"2015","unstructured":"Maury S, Chevret S, Thomas X, et al. Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-Negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized graall-R 2005 study. Blood. 2015;126(23):1\u20131.","journal-title":"Blood"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.118588"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261586"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)91950-9"},{"issue":"1","key":"e_1_3_2_10_1","first-page":"45","article-title":"Purine nucleoside phosphorylase deficiency","volume":"3","author":"Markert ML.","year":"1991","unstructured":"Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev. 1991;3(1):45\u201381.","journal-title":"Immunodefic Rev"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5676-9_40"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.10.5011"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.12.3848"},{"issue":"23","key":"e_1_3_2_14_1","first-page":"6498","article-title":"Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells","volume":"49","author":"Shewach DS","year":"1989","unstructured":"Shewach DS, Mitchell BS. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells. Cancer Res. 1989;49(23):6498\u20136502.","journal-title":"Cancer Res"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111514"},{"issue":"4","key":"e_1_3_2_16_1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.660","article-title":"Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells","volume":"61","author":"Cohen A","year":"1983","unstructured":"Cohen A, Lee JW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood. 1983;61(4):660\u2013666.","journal-title":"Blood"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0317"},{"issue":"15","key":"e_1_3_2_18_1","first-page":"3352","article-title":"2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies","volume":"55","author":"Lambe CU","year":"1995","unstructured":"Lambe CU, Averett DR, Paff MT, et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55(15):3352\u20133356.","journal-title":"Cancer Res"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1933"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000245326.65152.af"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.12.1601"},{"issue":"1","key":"e_1_3_2_22_1","first-page":"43","article-title":"Nelarabine: A new drug for hematological malignancies","volume":"86","author":"Rodriguez CO","year":"2001","unstructured":"Rodriguez CO, Gandhi V. Nelarabine: A new drug for hematological malignancies. Haematologica. 2001;86(Suppl 1\u201311):43\u201347.","journal-title":"Haematologica"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.09.002"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s4770"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868040-00004"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.199"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2142"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.426"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056754"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-329441"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08236.x"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.4239.4239"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3607"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<58::AID-CNCR8>3.0.CO;2-E"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.995"},{"issue":"11","key":"e_1_3_2_36_1","first-page":"2107","article-title":"Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells","volume":"3","author":"Rodriguez CO","year":"1997","unstructured":"Rodriguez CO Jr., Legha JK, Estey E, et al. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells. Clin Cancer Res. 1997;3(11):2107\u20132113.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"e_1_3_2_37_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","article-title":"Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor","volume":"12","author":"Estey E","year":"1994","unstructured":"Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12(4):671\u2013678.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116"},{"issue":"4","key":"e_1_3_2_39_1","first-page":"653","article-title":"Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule","volume":"2","author":"Seymour JF","year":"1996","unstructured":"Seymour JF, Huang P, Plunkett W, et al. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996;2(4):653\u2013658.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"e_1_3_2_40_1","first-page":"3100","article-title":"Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase","volume":"62","author":"Rodriguez CO","year":"2002","unstructured":"Rodriguez CO Jr., Mitchell BS, Ayres M, et al. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002;62(11):3100\u20133105.","journal-title":"Cancer Res"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2006-0017"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0606"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600961058"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.8724"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25470"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.312"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4428"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.679"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194527"},{"issue":"9","key":"e_1_3_2_52_1","first-page":"1059","article-title":"Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion","volume":"70","author":"Donehower RC","year":"1986","unstructured":"Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep. 1986;70(9):1059\u20131065.","journal-title":"Cancer Treat Rep"},{"issue":"10","key":"e_1_3_2_53_1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1200\/JCO.1984.2.10.1092","article-title":"Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia","volume":"2","author":"Ochs J","year":"1984","unstructured":"Ochs J, Sinkule JA, Danks MK, et al. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia. J Clin Oncol. 1984;2(10):1092\u20131097.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1986"},{"issue":"19","key":"e_1_3_2_55_1","first-page":"4937","article-title":"Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step","volume":"59","author":"Rodriguez CO","year":"1999","unstructured":"Rodriguez CO Jr., Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 1999;59(19):4937\u20134943.","journal-title":"Cancer Res"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.04.010"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2017.1262757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:28:40Z","timestamp":1770899320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2017.1262757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,8]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,2]]}},"alternative-id":["10.1080\/17474086.2017.1262757"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2017.1262757","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}